GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » 5-Year EBITDA Growth Rate
中文

Allergy Therapeutics (Allergy Therapeutics) 5-Year EBITDA Growth Rate

: 0.00% (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Allergy Therapeutics was 44.20% per year. The lowest was -130.80% per year. And the median was -10.90% per year.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics 5-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's 5-Year EBITDA Growth Rate falls into.



Allergy Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Allergy Therapeutics  (OTCPK:AGYTF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Allergy Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines